Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opko Health Inc (OPK)

Opko Health Inc (OPK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,013,365
  • Shares Outstanding, K 767,701
  • Annual Sales, $ 713,140 K
  • Annual Income, $ -53,220 K
  • EBIT $ -33 M
  • EBITDA $ 67 M
  • 60-Month Beta 1.34
  • Price/Sales 1.44
  • Price/Cash Flow 19.48
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 93.86% (+0.58%)
  • Historical Volatility 36.60%
  • IV Percentile 64%
  • IV Rank 19.20%
  • IV High 323.62% on 10/13/25
  • IV Low 39.29% on 01/24/25
  • Expected Move (DTE 10) 0.2380 (17.63%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 435
  • Volume Avg (30-Day) 406
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 58,517
  • Open Int (30-Day) 57,761
  • Expected Range 1.1119 to 1.5879

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 5
  • High Estimate -0.05
  • Low Estimate -0.09
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -800.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2150 +10.70%
on 11/11/25
1.3800 -2.54%
on 11/10/25
+0.0050 (+0.37%)
since 11/07/25
3-Month
1.2150 +10.70%
on 11/11/25
1.6000 -15.94%
on 10/06/25
-0.0650 (-4.61%)
since 09/09/25
52-Week
1.1100 +21.17%
on 08/01/25
2.0350 -33.91%
on 03/05/25
-0.2350 (-14.87%)
since 12/09/24

Most Recent Stories

More News
OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference

MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Piper Sandler 37 th Annual Healthcare Conference, being held December...

OPK : 1.3750 (+4.17%)
NextPlat Reports Third Quarter 2025 Results

Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026 

BABA : 156.21 (-1.21%)
NXPL : 0.6485 (-5.27%)
NXPLW : 0.0450 (+2.27%)
OPK : 1.3750 (+4.17%)
OPKO Health: Q3 Earnings Snapshot

OPKO Health: Q3 Earnings Snapshot

OPK : 1.3750 (+4.17%)
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results

MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights...

OPK : 1.3750 (+4.17%)
OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications

Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29,...

OPK : 1.3750 (+4.17%)
REGN : 697.27 (-0.85%)
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers

First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein  Two MDX2004 abstracts accepted for poster presentation at SITC Annual Meeting 2025 ...

OPK : 1.3750 (+4.17%)
OPKO Health to Report Third Quarter 2025 Financial Results on October 29

MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2025 after the close of the...

OPK : 1.3750 (+4.17%)
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

BURLINGTON, N.C. and MIAMI , Sept. 15, 2025 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and  OPKO Health,...

OPK : 1.3750 (+4.17%)
LH : 258.73 (-0.47%)
OPKO Health: Q2 Earnings Snapshot

OPKO Health: Q2 Earnings Snapshot

OPK : 1.3750 (+4.17%)
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results

MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2025. Highlights from the second...

OPK : 1.3750 (+4.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and...

See More

Key Turning Points

3rd Resistance Point 1.4233
2nd Resistance Point 1.3867
1st Resistance Point 1.3533
Last Price 1.3750
1st Support Level 1.2833
2nd Support Level 1.2467
3rd Support Level 1.2133

See More

52-Week High 2.0350
Fibonacci 61.8% 1.6817
Fibonacci 50% 1.5725
Fibonacci 38.2% 1.4634
Last Price 1.3750
52-Week Low 1.1100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar